|
April 2025
Dear Drug Safety Update Subscriber,
This is a final reminder that we have now launched our new monthly safety bulletin; the MHRA Safety Roundup. To receive further issues of this bulletin, please subscribe.
You will continue to receive e-mail alerts for Drug Safety Updates which will be published throughout the month, however to receive our monthly safety bulletin you must subscribe separately. Our Safety Roundup includes a summary of all safety alerts published during the month as well as safety-related news.
Please see below for a snapshot of April's Safety Roundup, published today.
This month's MHRA Safety Roundup includes:
- Drug Safety Update on Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk
- Drug Safety Update on Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
- Letters, medicines recalls and device notifications sent to healthcare professionals in March and April 2025
- News on BCR-ABL tyrosine kinase inhibitors and interstitial lung disease, new guidance on risk minimisation materials, update to UK clinical trials
April's Safety Roundup is now available to read as a downloadable document or on the GOV.UK website.
It's easy to report
Report a suspected adverse drug reaction online
or download the Yellow Card app
Thank you,
The Medicines and Healthcare products Regulatory Agency
|
